SMO ClinPlus Co. Ltd. Total Liabilities
SMO ClinPlus Co. Ltd. total liabilities. Based on the latest financial reports, SMO ClinPlus Co. Ltd. (301257) has total liabilities worth CN¥243.37 Million CNY (≈ $35.61 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 301257 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of SMO ClinPlus Co. Ltd. (2019–2025)
Total liabilities of SMO ClinPlus Co. Ltd. from 2019 to 2025. This chart illustrates how SMO ClinPlus Co. Ltd.'s total liabilities have evolved over time, based on quarterly financial data.
SMO ClinPlus Co. Ltd. Competitors by Total Liabilities
The table below lists competitors of SMO ClinPlus Co. Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shape Australia Corporation Ltd
AU:SHA
|
Australia | AU$303.84 Million |
|
Zuming Bean Products Co Ltd
SHE:003030
|
China | CN¥1.36 Billion |
|
Schweiter Technologies AG
LSE:0QR1
|
UK | £328.10 Million |
|
Sinopec Oilfield Service Corporation
F:YIZH
|
Germany | €66.96 Billion |
|
Steelcast Limited
NSE:STEELCAS
|
India | Rs-3.95 Billion |
|
Shandong Longji Machinery Co Ltd
SHE:002363
|
China | CN¥790.25 Million |
|
Yulon Nissan Motor Co Ltd
TW:2227
|
Taiwan | NT$4.69 Billion |
|
Zhong Fu Tong Co Ltd
SHE:300560
|
China | CN¥1.64 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down SMO ClinPlus Co. Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see SMO ClinPlus Co. Ltd. (301257) total assets.
Liquidity & Leverage Metrics
SMO ClinPlus Co. Ltd. Total Liabilities Ratios Explained
SMO ClinPlus Co. Ltd. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.99 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SMO ClinPlus Co. Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SMO ClinPlus Co. Ltd. (2019–2025)
The table below shows the annual total liabilities of SMO ClinPlus Co. Ltd. from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥274.41 Million ≈ $40.16 Million |
+6.99% |
| 2024-12-31 | CN¥256.48 Million ≈ $37.53 Million |
-10.39% |
| 2023-12-31 | CN¥286.22 Million ≈ $41.88 Million |
+37.11% |
| 2022-12-31 | CN¥208.75 Million ≈ $30.55 Million |
+19.01% |
| 2021-12-31 | CN¥175.41 Million ≈ $25.67 Million |
+37.65% |
| 2020-12-31 | CN¥127.43 Million ≈ $18.65 Million |
+66.06% |
| 2019-12-31 | CN¥76.74 Million ≈ $11.23 Million |
-- |
About SMO ClinPlus Co. Ltd.
SMO ClinPlus CO.,LTD. provides site management services in research and development in pharmaceuticals, medical devices, and health-related products in China. It offers clinical trial site management organization services to pharmaceuticals, medical devices, CRO companies, etc. The company offers preliminary modeling and preparation plans, trial site initiation, on-site execution, and project man… Read more